| Home Market Dynamics Macro Trends Sector Trends Company Insights AI Investing Strategies Sign Up Login |
Sector: Pharmaceuticals
| Eli Lilly's acquisition strategy and expansion into cancer treatments, particularly through the $7 billion acquisition of Kelonia Therapeutics, highlight its focus on enhancing product offerings and innovation in the oncology market. Additionally, the launch of new therapies like Foundayo showcases their commitment to innovative product development, with promising early prescription rates contributing to growth potential. However, challenges remain in the weight-loss sector, as initial performance of some products indicates a cautious market reception. |
| The price action of Eli Lilly (LLY) is impacted by broad market risk appetite, sector price trend, company-specific performance and market structure. The trend sentiment at -1.9 is very bearish. The market sentiment at 0.4 is modestly bullish. Trend sentiment measures the current trend of the stock price, and market sentiment reflects what market participants collectively think where the price will move next. There is no clear direction for LLY since trend sentiment and market sentiment are at the opposite directions. The positive sentiment force for sector is at 0.8, and the negative at -0.4 on 2026-04-27. The forces of Stock Price Trend (-1.9), and Sector Price Trend (-1.2) will drive down the price. The forces of Valuation Sentiment (0.5), Option Sentiment (0.8), Price Level Sentiment (1), Market Risk Appetite (1), and Sentiment towards Fundamentals (1.7) will drive up the price. The sentiment for Sector Price Trend is calculated based on the price trend of related sector ETF. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Appetite is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. The price level reaches 100 at Bollinger upper band, and zero at lower band. |
Sign up to reveice notifications on Market Movers
| LLY | ||||||||||||||
| Date | Attention | Price | StdDev | Price Level | Change | 10 Day Trend | Trend Sentiment | Hourly Trend Sentiment | Hourly StdDev | Market Sentiment | Action | P | Fund. | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-27 | 0%(0.1%) | 868.14 | 2.62% | -7 | -1.81% | -0.67% | -1.9 | -0.7 | 1.8% | 0.4 | Short | 70% | 1.7 | 5.5 |
| 2026-04-26 | 0%(0.3%) | -1.6 | -0.7 | 0.4 | 2.1 | -1 | ||||||||
| 2026-04-25 | 0%(0.4%) | -1.6 | -0.7 | 0.4 | 2.1 | -1 | ||||||||
| 2026-04-24 | 1%(0.4%) | 884.18 | 2.45% | 8 | -3.6% | -0.6% | -1.6 | -0.5 | 2% | 0.6 | Short | 55% | 2.3 | -1.8 |
| 2026-04-23 | 0%(0.3%) | 917.23 | 2.27% | 45 | -0.46% | -0.41% | -0.1 | 0 | 0.7% | 1.2 | Long | 55% | 2.6 | -1 |
| 2026-04-22 | 0%(0.3%) | 921.5 | 2.26% | 50 | 2.03% | -0.35% | 0.1 | 0.3 | 1.2% | 1.4 | Long | 55% | 2.7 | 5.7 |
| 2026-04-21 | 0%(0.3%) | 903.19 | 2.35% | 30 | -1.96% | -0.3% | -0.7 | -0.2 | 1.4% | 0.8 | Short | 55% | 2.5 | -1 |
| 2026-04-20 | 1%(0.3%) | 921.27 | 2.28% | 51 | -0.6% | -0.05% | -0.2 | -0.1 | 0.9% | 1.5 | Short | 55% | 2.2 | 6.2 |
| 2026-04-19 | 1%(0.1%) | -0.4 | -0.1 | 1 | 1.4 | 5.5 | ||||||||
| 2026-04-18 | 0%(0%) | -0.4 | -0.1 | 1 | 1.4 | -1 | ||||||||
| Short is the preferred trading strategy with 70% chance of being right. Both trend sentiment and hourly trend are very weak. Wait action is recommended in three scenarios with either high uncertainty or high risk: 1. The trend sentiment and market sentiment are at the opposite directions. 2. Both trend sentiment and market sentiment are positive, but the price level is elevated. 3. Both trend sentiment and market sentiment are negative, but the price level is depressed. In an uptrend, as an investor, you may want to wait for the pullback to open long position. In a downtrend, the price will likely rebound after huge decline. As an investor, you may want to wait for the rebound to exit long position. | ||||||||||||||
| Market sentiment will accelerate the current trend when both trend sentiment and market sentiment are at the same direction. Market sentiment will generate volatility when it's at the opposite direction of the trend sentiment. News sentiment measures the daily emotion of the market. News sentiment may impact the daily price change while market sentiment is a more stable and consistent moving force. | ||||||||||||||
| Analysis | ||
| ● Eli Lilly (LLY) – Equity Research Report Tue. Mar 17, 2026 | ||
| 2026-04-27 22:48:52 Analysts' views on upcoming catalysts that could drive growth for Eli Lilly, especially regarding eloralintide and combination therapies. |
| 2026-04-27 22:48:52 The potential impact of Eli Lilly’s Foundayo launch on company growth and market presence. |
| 2026-04-27 17:48:56 Analysts believe that eloralintide and combination therapies could significantly impact the company's growth trajectory. |
| 2026-04-27 17:48:56 The article discusses the potential growth driven by Eli Lilly's Foundayo launch and its future prospects. |
| 2026-04-27 17:01:41 The emphasis on diversified healthcare strategies, including ETF spotlighting and target price adjustments for stocks like UnitedHealth, illustrates ongoing trends in the healthcare market. |
| 2026-04-27 17:01:41 Significant developments in drug pipelines, particularly for Eli Lilly, suggest a competitive landscape focused on innovative treatments and advancements in therapies. |
| 2026-04-27 17:01:41 Recent fluctuations in stock prices, such as Eli Lilly’s drop, reflect market reactions and investor sentiment towards pharmaceutical stock performances. |
| 2026-04-27 17:01:41 Analysts are optimistic about upcoming earnings reports from major pharmaceutical companies, including Eli Lilly, indicating positive growth amidst industry challenges. |
| 2026-04-27 17:01:41 Eli Lilly's strategic acquisition of Ajax Therapeutics highlights robust investment activity in biopharmaceuticals, particularly focused on enhancing treatment options in blood cancers. |
| 2026-04-27 11:50:10 The launch of Foundayo and other therapies signifies significant innovation within the company. |
| 2026-04-27 11:50:10 Analysts express optimism about the potential growth driven by Eli Lilly’s products and innovations. |
| 2026-04-27 09:36:04 Eli Lilly's move is indicative of a growing focus on blood cancer therapies within the pharmaceutical industry. |
| 2026-04-27 09:36:04 The large financial commitment of up to $2.3 billion demonstrates significant investment potential in the biotechnology field. |
| 2026-04-27 09:36:04 Eli Lilly's acquisition of Ajax Therapeutics highlights a strategic move into blood cancer treatments, signaling optimism in the healthcare sector. |